KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Pacific Biosciences Of California (PACB) Depreciation Expense (2022 - 2025)

Pacific Biosciences Of California has reported Depreciation Expense over the past 4 years, most recently at $2.7 million for Q4 2025.

  • Quarterly results put Depreciation Expense at $2.7 million for Q4 2025, down 3.27% from a year ago — trailing twelve months through Dec 2025 was $13.0 million (down 5.62% YoY), and the annual figure for FY2025 was $13.0 million, down 5.62%.
  • Depreciation Expense for Q4 2025 was $2.7 million at Pacific Biosciences Of California, up from $2.5 million in the prior quarter.
  • Over the last five years, Depreciation Expense for PACB hit a ceiling of $5.1 million in Q1 2025 and a floor of $2.3 million in Q1 2022.
  • Median Depreciation Expense over the past 4 years was $2.8 million (2023), compared with a mean of $3.0 million.
  • Peak annual rise in Depreciation Expense hit 58.36% in 2025, while the deepest fall reached 41.31% in 2025.
  • Pacific Biosciences Of California's Depreciation Expense stood at $2.5 million in 2022, then grew by 18.48% to $3.0 million in 2023, then decreased by 5.68% to $2.8 million in 2024, then decreased by 3.27% to $2.7 million in 2025.
  • The last three reported values for Depreciation Expense were $2.7 million (Q4 2025), $2.5 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.